Posted on Leave a comment

New COVID-19 Clinical Trial Announced To Treat Over 90% of Patients With Underlying Medical Conditions

A new clinical trial is being announced today that could significantly increase the rate of recovery for COVID-19 patients with underlying health conditions and save lives! Circularity Healthcare’s trial will help some of the most at-risk patients suffering from complications due to diabetes, poor circulation, hypertension, cardiovascular disease and high blood pressure. The trial will involve the use of Circularity’s already FDA-approved drug and IDE device D’OXYVA® (deoxyhemoglobin vasodilator) – a non-toxic, non-invasive microcirculation transdermal device.  It is the first biotech solution of its kind to improve overall oxygen-rich blood flow. The device has been shown to significantly heal diabetic wounds, reduce the risks of amputations, prevent sepsis and septic shock,  improve blood pressure and general vital organ function of the pancreas, liver, brain and kidneys, while increasing overall health for some of the most vulnerable patients. 

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

“Anyone who suffers from an underlying condition should know that this proven treatment option is available,” says Circularity Healthcare CEO Norbert Kiss. “Every medical report released so far shows that severe COVID-19 patients need blood oxygenation and blood thinners. The overwhelming majority of patients have diabetes and cardiovascular issues beyond pulmonary complications and they all have sepsis setting in early on. These are the exact main vitals and chronic diseases D’OXYVA improves like no other medication currently available on the market.”

The recommendation for this new treatment is based on the following:

  • After eight years of three dozen human studies with leading experts at some of the most prestigious universities and hospitals in the world (including Penn State and Airlangga University), zero adverse effects were reported. D’OXYVA is currently expanding its Phase 3 trial with Professor David G. Armstrong and his colleagues.
  • The pharmaceutical-grade CO2 utilized by the D’OXYVA device has already been approved by the FDA (it is the same CO2 drug already readily available in every hospital and provided by the same supplier). There is just a 1-2 week IRB approval to launch the trials at any location due to the investigational device exemption (IDE) status of D’OXYVA. Additionally, with the device factory S.-based in Fremont, CA, all the regulated products are also readily-available to launch the trial.
  • The effects of transdermal CO2 have been widely noted in wound care as demonstrated in clinical studies. Healing, closure, prevention against sepsis and septic shock and recovery of an ulcer (non-healing) due to diabetes and cardiovascular complications are much faster and often successful where other modalities have failed.
  • All research projects performed up to date have consistently recorded a significant decrease in systolic blood pressure (from the heart) and diastolic (return to the heart) blood pressure. These results have been consistent throughout all study time periods   up to 240 minutes (the longest time period evaluated after treatment).
  • Systemically, CO2 therapy has shown great success to improve the healthcare of patients with high blood pressure, general vital organ function of patients with high blood pressure, and general vital organ function like that of the pancreas, liver, brain, and kidneys

The clinical trials are now waiting IRB approvals and are about to launch under existing contracts at multiple sites including top U.S. universities such as Harvard, Yale, M.I.T, USC, and UCLA, with more physicians and patients being invited to participate. Since the product can be monitored at home, potential patients do not have to be currently admitted to a hospital in order to take part in the trial. For more information on the trial or to sign up, please visit https://doxyva.com/covid-19/ or call 626.240.0956.

About Circularity Healthcare, LLC
Circularity Healthcare, LLC, located in Los Angeles, CA, is a private biotech and MedTech products and services company that designs, makes, markets, sells, distributes, and licenses its patented and patent-pending technologies, such as its flagship non-invasive deoxyhemoglobin vasodilator product line, D’OXYVA®. One of the main mechanisms underlying D’OXYVA’s science received the Nobel Prize for Medicine in 2019. Circularity enters into exclusive agreements with manufacturers to launch products in large and small clinics and hospitals to help enhance their profits and credit profiles with a wide variety of advanced products and services. In addition, Circularity Healthcare assists in the financing of equipment, working capital, and patient financing at industry-leading terms and speed.

For more information, please visit http://www.circularityhealthcare.com or http://doxyva.com; doctors (Rx only) visit http://wound.doxyva.com and send your general inquiries via the Contact Us page. For specific inquiries, contact Circularity Customer Care at info(at)doxyva(dot)com, info(at)circularityhealthcare(dot)com, or by phone (toll free) at 1-855-5DOXYVA or 1-626-240-0956.

Forward-Looking Information
This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Join Professional Fitness Icon Eva Marie in a 30-Day D’OXYVA Challenge

Former professional wrestler, actress, and fitness model Eva Marie recently announced a 30-day challenge based on a daily application of D’OXYVA. In a five-minute video on her Instagram page, she and her husband announced that they would both be testing the product to determine the impact on their health and vitality. Marie and the makers of D’OXYVA are also hosting a contest in which her followers can enter to win their own 30-day challenge package.

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

Having been an athlete most of her life, Eva Marie has always been a natural fitness enthusiast. After winning the 2012 Powertech Model competition, she joined the WWE in May 2013. Through her time as a wrestler, manager, and actor with the Total Divas, she has always strived for maximum fitness. In recent years, she and her husband have launched social media channels focusing on fashion and fitness and helmed a number of entrepreneurial enterprises, including the Natalie Eva Marie X Ryderwear fashion collection and NEM Fit workout program.

30-Day D’OXYVA Challenge

In part because of the COVID-19 pandemic, Eva Marie and her husband decided to spend their physical distancing time experimenting with various health and wellness programs. Beginning April 17, 2020, the couple decided to use D’OXYVA for the next thirty days and report the results to her fans. To better understand the impact, they will take a few baseline health measurements, such as blood oxygen levels. After the challenge, they will take more measurements to provide anecdotal and statistical comparisons. The video also demonstrates the non-invasive application of the D’OXYVA product.

Why D’OXYVA?

D’OXYVA is a revolutionary new application providing a number of powerful health benefits. At its core, the five-minute, noninvasive application exposes the body to a painless vapor of purified CO2 molecules across the skin. The body responds to this exposure by increasing circulation to the affected areas. Improvements in microcirculation have been proven to lead to a number of positive health outcomes, including greater healing and immune responses.

D’OXYVA has been shown to eliminate nearly all spider and varicose vein markings and speed the healing of open wounds. Improvements in blood flow and nerve stimulation can relieve chronic pain from conditions such as neuropathy or advanced diabetes. As an added benefit, D’OXYVA is a single product that can replace a number of treatments for various conditions. Users can save money and time by consolidating therapies into one application.

Benefits for Healthy People

D’OXYVA is not just for people suffering from chronic conditions. Daily use of D’OXYVA can also provide improvements in circulation and potentially produce benefits related to general fitness, cardiovascular efficiency, and endurance. Eva Marie’s 30-day challenge is intended to allow her to experience and chart these results for the general public, and Marie and the makers of D’OXYVA want to share these benefits with you!

Two lucky people will receive a complete month’s supply of D’OXYVA, including cartridges and the oximeter, to measure blood oxygen levels. Winners will be chosen at random on Monday, April 20, 2020. To enter your name:

 

For More Information:

Don’t wait to join Eva Marie in her 30-day challenge of D’OXYVA! Even if you don’t win, visit https://doxyva.com/shop/ today for great deals on equipment and supplies. You can find sales of up to 35% off for a limited time only!

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Non-Invasive Microcirculatory Device Could Help COVID-19 Patients With Underlying Medical Conditions

covid 19

Read article in PRWeb

According to the CDC, nearly 90% of Americans being hospitalized with COVID-19 have an underlying medical condition. Healthcare technology company Circularity Healthcare, creators of D’OXYVA®, is looking to help these patients treat those conditions faster to better their chances of recovery. D’OXYVA® (deoxyhemoglobin vasodilator), the first biotech solution of its kind, provides non-invasive, transdermal microcirculation to improve overall oxygen-rich blood flow – an effective treatment option for a variety of conditions including diabetes, hypertension, cardiovascular issues, COPD, and high blood pressure.

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

“D’OXYVA is aimed at helping millions of people improve their health and their immune response,” says Circularity Healthcare CEO Norbert Kiss. “We are confident this device can save lives in the fight against the Coronavirus by helping repair the body’s functions in people with underlying conditions.” D’OXYVA speeds up the body’s healing process by improving micro and macro circulation and the autonomic nervous system (ANS), detoxifying the liver and kidney, reducing inflammation, and increasing oxygenation and delivery of nutrients. It is the only clinically-tested, non-invasive, portable, transdermal microcirculatory regenerative solution device.

The over-the-counter product is intended to ease the expense and inconvenience of time-consuming doctor visits by offering affordable and effective management of conditions that can take place in the comfort of your own home. “This is truly the future of optimized healthcare,” says Kiss. “D’OXVYA provides an advanced technology that offers a painless solution to help people manage chronic health conditions and see measurable results within a matter of weeks. This is a great way to save time and money by reducing the reliance on opioids and other expensive medications and office visits.”

Extensive clinical research conducted over an eight-year period has already shown incredible success rates. Trials have included over three dozen human clinical studies including double-blind, randomized, and placebo-controlled studies at Pennsylvania State University. The company is now significantly expanding Phase 3 human clinical trials working with the top ten universities in the U.S. targeting underlying conditions specific to COVID-19 risk factors such as oxygen-rich microcirculation in lungs, the heart, kidneys and other vital organs as well as inflammatory markers.

The science used to create the device received a 2019 Nobel Prize in Physiology Medicine. D’OXYVA works by utilizing FDA-cleared, non-toxic molecules (over-the-skin deoxyhemoglobin vasodilator) that deliver a vapor of pharmaceutical-grade CO2 and water to the peripheral microcirculation. This vapor is delivered through the placement of the D’OXYVA device over the thumb for a 5-minute period. The CO2 then travels into the microcirculation of the skin, where it causes a vasodilation that leads to increased perfusion. Since its introduction in 2012, the physician-recommended, easy-to-use device has helped users track and regain their health by repairing or growing new vessels and significantly improving nerve activities in the body.

“The fact is that D’OXYVA increases the effectiveness of the Microcirculatory System,” says Dr. Jim Bledsoe, PHD and Holistic Practitioner. “Increasing the blood flow will help the body improve itself.”

D’OXYVA is currently available OTC online.

The company is actively accepting donation requests from nurses and doctors to provide D’OXYVA for immediate lifesaving treatment of hospital patients in critical condition due to its Investigational Device Exemption (IDE) status under FDA regulations. For more information, please visit doxyva.com/covid-19 or call 626.817.6698.

About Circularity Healthcare, LLC Circularity Healthcare, LLC, located in Los Angeles, CA, is a private biotech and MedTech products and services company that designs, makes, markets, sells, distributes, and licenses its patented and patent-pending technologies, such as its flagship non-invasive deoxyhemoglobin vasodilator product line, D’OXYVA®. One of the main mechanisms underlying D’OXYVA’s science received the Nobel Prize for Medicine in 2019. Circularity enters into exclusive agreements with manufacturers to launch products in large and small clinics and hospitals to help enhance their profits and credit profiles with a wide variety of advanced products and services. In addition, Circularity Healthcare assists in the financing of equipment, working capital, and patient financing at industry-leading terms and speed. For more information, please visit http://www.circularityhealthcare.com or http://doxyva.com; doctors (Rx only) visit http://wound.doxyva.com and send your general inquiries via the Contact Us page. For specific inquiries, contact Circularity Customer Care at info(at)doxyva(dot)com, info(at)Circularity Healthcare(dot)com, or by phone (toll free) at 1-855-5DOXYVA or 1-626-240-0956. Forward-Looking Information This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.
Posted on Leave a comment

Effects of D’OXYVA® on overall fitness status, heart rate variability and autonomic nervous function

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

D’OXYVA® is a transdermal CO2 delivery system shown to produce higher oxygen unloading by hemoglobin1, thereby increasing oxygen-rich blood flow in the local microcirculatory system, which in turn leads to better blood perfusion and tissue oxygenation. Among its other health benefits, D’OXYVA® has been also validated as a successful means of improving the autonomic nervous system.

Share this:

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

D’OXYVA® uses vaporized ultra-purified carbon dioxide to improve the body’s self-healing functions. It delivers this non-toxic compound via a non-invasive skin-delivery method, which has been shown to be more effective and safer than inhalation, a routine delivery method in hospital settings. The FDA-approved medical CO2 gets mixed with water inside the device, producing an active solution of supersaturated CO2 and water (H2O) vapor that improves skin microcirculation and/or blood circulation after dissolving into the skin2.

Good blood circulation has many important health benefits. Among the most prominent is the optimal oxygenation of bodily tissues and organs, which allows for efficient functioning of the heart, lungs and muscles. Active blood circulation also improves the immune response against disease by allowing the better transportation of white blood cells throughout the body. Furthermore, proper blood circulation improves cellular detoxification, while waste removal becomes more efficient3.

HRV4 is the variation in the time interval between consecutive heartbeats in milliseconds. It is highly influenced by hormones, metabolic and cognitive processes, exercise and stress5. A healthy heart can be identified via its HRV since it would show a constant variation between heartbeats. Therefore, HRV is an excellent measure of overall health and fitness status6.

HRV is regulated by the autonomous nervous system (ANS), by both its sympathetic (SYM) and parasympathetic (VAG) branches, and is accepted as a non-invasive marker of ANS activity7. Therefore, HRV is an interesting and noninvasive way to identify ANS imbalances. If a person is in a fight-or-flight mode, which is dominated by the sympathetic system, the variation between heartbeats will be low. If one is in a more relaxed state, this variation will be high. That is to say, the healthier the ANS, the higher the HRV, and the faster one can adapt his or her heartbeat to the circumstances, leading to more resilience and flexibility, higher stress resistance and better cardiovascular health8. HRV can also be used as a means to inform people about their lifestyle and motivate those who are considering doing something else to become healthier. HRV is typically higher when the heart is beating slowly, and lower when the heart starts to beat faster, such as during stress or exercise. The HRV naturally changes on a daily basis, based on activity and stress levels, but in chronically stressed people, the natural interplay between the two subsystems can be altered, and the body can be stuck in a sympathetically dominant fight state, with low HRV and high stress hormone levels, even at rest8.

To check HRV, the standard is to analyze a long strip of an electrocardiogram (ECG). The time between beats is called the R-R interval and is measured in milliseconds (ms). There are many ways to measure HRV, but one of the most common is the standard deviation of normal to normal R-R intervals (SDNN). Some studies have found that in 24-hour monitoring testing, SDNN values under 50 ms are considered unhealthy, between 50-100 ms may indicate compromised health, and above 100 ms are healthy9. But exactly what these measurements indicate will vary from person to person because of their high dependency on age, gender, fitness level, medical history and genetics10.

Improving your HRV has a number of proven health benefits, including a decreased risk of cardiovascular disease11, enhanced cognitive performance and creativity12, a potentially decreased risk for Alzheimer’s13 and improved anxiety levels14. Moreover, athletes can benefit from HRV by it enhancing their athletic performance and as an indicator of the need to adjust one’s training intensity15.

That is why we chose HRV as a proxy to characterize the effects of D’OXYVA® on overall health and fitness in normal subjects. D’OXYVA®—a clinically proven16 method to improve on many health conditions, from diabetic foot ulcer improvement to pain management—was the focus of a preliminary clinical study to assess respiratory function, HRV and related autonomous system function in 13 patients (10 men, 3 women), aged 32 years, on average (32.5±12.7), with a mean height of 169±7.3 centimeters and a mean weight of 65.9±10.1 kilograms. Importantly, to be recruited for the study, the patients could not have a previous history of cardiac or respiratory disease.

The effects of D’OXYVA® were measured at several intervals after application (first after 5 minutes, then after 30 minutes and one last time an hour after CO2 application) and compared to a baseline recording. Among the recorded values were some related to respiratory function (like oxygen saturation, SpO2 and CO2 pressure and ETCO2), heart function (heart rate, RRIV and SDNN) and autonomous nervous system function (parasympathetic function VAG, sympathetic function SYM and balance ASN).

The data gathered after D’OXYVA® application showed improved blood oxygenation just 30 minutes after treatment, which was more or less maintained up to an hour after treatment. Conversely, the CO2 pressure was greatly diminished at a half hour after treatment, which is inversely correlated with the improved blood oxygenation observed at that time point. Naturally, the later small decrease in SpO2 is also reflected in the inverse change in ETCO2.

Secondly, heart function analysis showed a decreased heart rate just 5 minutes after D’OXYVA® treatment. This slight decrease in heart rate was correlated with a large decrease in normal pitch change in R-R (RRIV), which was maintained for the entire recording period and up to an hour afterward. The NN spacing standard deviation (SDNN) was not affected by the intervention, which is an indicator of the good health status of the patients included in the study.

Lastly, a range of parameters related to AN) function were examined. These included SYM and VAG function, their relative balance of activity as well as overall autonomous system function and ANS age, which is related to biological age and acts as a proxy for premature aging in the nervous system. Sympathetic function experienced a stark decrease after D’OXYVA® application, whereas parasympathetic function slightly increased over time after the treatment. The balance between SYM and VAG was mainly driven by the change in SYM and therefore followed the same dynamic.

The plot of modulation of sympathetic function shows effective SYM self-regulation, with small variations after treatment. General ANS function improved half an hour after application, whereas ANS age marginally improved after treatment, starting just 5 minutes after treatment.

In summary, the results after a single application of D’OXYVA®-mediated transdermal CO2 delivery showed increased oxygen concentration and lower carbon dioxide concentration in the blood just 30 minutes after treatment, which may persist over 60 minutes. As for heart function, a tendency was observed toward decreased RRIV and stabilization of overly high HRV, which would point to a reduction in risk of cardiac arrhythmia. The analysis of autonomous nervous system function showed a balanced sympathetic and parasympathetic tone, probably due to parasympathetic effects.

All in all, the results of this preliminary study vouch for the positive influence of D’OXYVA®-mediated transdermal CO2 delivery on blood oxygenation, heart function and autonomous system function, thereby displaying the beneficial effects of D’OXYVA® on overall health function and further supporting its use as a stress-free, complication-free, complementary method for improving HRV. Regular use of D’OXYVA®, in combination with a Mediterranean diet, good sleep, cold showers and/or deep breathing exercise like yoga17, can drive a maintained, noticeable improvement in HRV and consequently in overall health and fitness status. Especially for people under stressful life conditions or those enduring strong exercise routines, like professional sportsmen and women, D’OXYVA® offers an extra boost to their overall health by increasing their HRV values.

Bibliography

  1. Rogers, L. C., Muller-Delp, J. M. & Mudde, T. A. Transdermal delivery of carbon dioxide boosts microcirculation in subjects with and without diabetes. Information summary for healthcare professionals. Circulatory Healthcare Inc.
  2. Introducing D’OXYVA – What is D’OXYVA? D’OXYVA https://doxyva.com/about-doxyva/.
  3. Good Blood Circulation, Why Is It So Important? D’OXYVA https://doxyva.com/2019/11/02/why-good-blood-circulation-is-important-for-overall-health/ (2019).
  4. Heart rate variability. Wikipedia (2020).
  5. Kim, H.-G., Cheon, E.-J., Bai, D.-S., Lee, Y. H. & Koo, B.-H. Stress and Heart Rate Variability: A Meta-Analysis and Review of the Literature. Psychiatry Investig. 15, 235–245 (2018).
  6. What is Heart Rate Variability (HRV) & why does it matter? | Firstbeat Blog. Firstbeat https://www.firstbeat.com/en/blog/what-is-heart-rate-variability-hrv/.
  7. Ernst, G. Heart-Rate Variability—More than Heart Beats? Front. Public Health 5, (2017).
  8. MD, M. C. Heart rate variability: A new way to track well-being. Harvard Health Blog https://www.health.harvard.edu/blog/heart-rate-variability-new-way-track-well-2017112212789 (2017).
  9. Shaffer, F. & Ginsberg, J. P. An Overview of Heart Rate Variability Metrics and Norms. Front. Public Health 5, (2017).
  10. Short-Term Heart Rate Variability—Influence of Gender and Age in Healthy Subjects. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0118308.
  11. Blumenthal, J. A. et al. Effects of Exercise and Stress Management Training on Markers of Cardiovascular Risk in Patients With Ischemic Heart Disease: A Randomized Controlled Trial. JAMA 293, 1626–1634 (2005).
  12. Gruzelier, J. H., Thompson, T., Redding, E., Brandt, R. & Steffert, T. Application of alpha/theta neurofeedback and heart rate variability training to young contemporary dancers: state anxiety and creativity. Int. J. Psychophysiol. Off. J. Int. Organ. Psychophysiol. 93, 105–111 (2014).
  13. [Heart and brain — the influence of psychiatric disorders and their therapy on the heart rate variability] – Abstract – Europe PMC. http://europepmc.org/article/MED/15806437.
  14. Lee, J., Kim, J. K. & Wachholtz, A. The benefit of heart rate variability biofeedback and relaxation training in reducing trait anxiety. Hanguk Simni Hakhoe Chi Kongang Korean J. Health Psychol. 20, 391–408 (2015).
  15. Paul, M., Garg, K. & Singh Sandhu, J. Role of Biofeedback in Optimizing Psychomotor Performance in Sports. Asian J. Sports Med. 3, 29–40 (2012).
  16. CLINICAL EVIDENCE. D’OXYVA https://doxyva.com/clinical-evidence/.
  17. 5 ways to improve your Heart Rate Variability (HRV). Myithlete https://www.myithlete.com/improve-heart-rate-variability-hrv/ (2019).

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Always Ready to D’OXYVA, Never Have to Order

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.
Circularity Healthcare’s Autopay-Autoship Program means your D’OXYVA supplies are always on-hand right-here, right-now.
You already know that D’OXYVA’s daily continued application for at least 8 weeks has been proven to deliver greater results for your physical restoration and mental renewal for an enhanced overall quality of life.

Share this:

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

Now you can skip the website, cart and checkout process and receive a 6-month supply of D’OXYVA Easytwist cartridges delivered directly to your doorstep automatically — plus, enjoy FREE shipping on your order and savings up to $360 off the regular order price.

Circularity Healthcare’s D’OXYVA Autopay-Autoship Program includes 6 months of D’OXYVA supplies for $179 per month, payable with any major banking card or your PayPal account.

This convenient, reliable, and affordable program, now in its second decade of operation, was born of Circularity Healthcare’s unwavering commitment to serving its customers with the utmost care and support.

“We never stop thinking about our customers satisfaction — this program is only one of the many programs we have in place that our customers can choose from that will fit to their needs,” says Jennifer Boadilla-Pelaez, Senior Sales and Marketing Manager, and Creative Director of Circularity Healthcare.

For more information and to start your Circularity Healthcare’s D’OXYVA Autopay-Autoship Program, click the button below.

HOW D’OXYVA CAN HELP?

D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Posted on Leave a comment

Circularity Healthcare, LLC Receives 2019 Pasadena Award

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

Pasadena Award Program Honors the Achievement

PASADENA November 30, 2019 — Circularity Healthcare, LLC has been selected the 2nd time in 3 years for the 2019 Pasadena Award in the Healthcare Products Developer and Manufacturer category by the Pasadena Award Program.

Each year, the Pasadena Award Program identifies companies that we believe have achieved exceptional marketing success in their local community and business category. These are local companies that enhance the positive image of small business through service to their customers and our community. These exceptional companies help make the Pasadena area a great place to live, work and play.

Various sources of information were gathered and analyzed to choose the winners in each category. The 2019 Pasadena Award Program focuses on quality, not quantity. Winners are determined based on the information gathered both internally by the Pasadena Award Program and data provided by third parties.

About Pasadena Award Program

The Pasadena Award Program is an annual awards program honoring the achievements and accomplishments of local businesses throughout the Pasadena area. Recognition is given to those companies that have shown the ability to use their best practices and implemented programs to generate competitive advantages and long-term value.

The Pasadena Award Program was established to recognize the best of local businesses in our community. Our organization works exclusively with local business owners, trade groups, professional associations and other business advertising and marketing groups. Our mission is to recognize the small business community’s contributions to the U.S. economy.

SOURCE: Pasadena Award Program

CONTACT:
Pasadena Award Program
Email: PublicRelations@online-best-advisory2019.org
URL: http://www.online-best-advisory2019.org

Posted on Leave a comment

Innovative Collaboration: The Cutting Edge of Medicine Goes “Behind The Scenes”

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

LOS ANGELES (PRWEB) DECEMBER 11, 2019

Circularity is partnering with Telly Award-Winning “Behind the Scenes” to provide regular, ongoing, high-quality content from leading experts in a variety of fields with an initial focus on microcirculation science, regenerative medicine, and advanced wound healing and related symptoms. The show reaches 60 million households domestically.

“Behind The Scenes with Host Laurence Fishburne” is a public television icon that has won numerous awards and delivers precision idea-telling at its best. Circularity is an innovative healthcare organization that is health-bent on their trademarked slogan: “Improving Lives by Improving Blood Flow.” Their coming together to bring forward the ideas of modern health science on a stellar entertainment platform can only make for riveting content going forward. Viewers will find themselves in a win-win situation.

Watching informative content via this stylized venue will leave viewers feeling quite satisfied with their television watching experience. It is time well spent and information precisely delivered.

A Little More About Circularity

Circularity is concerned with bringing the very best in Health care innovation to the public. In so doing, they have manufactured a product called D’OXYVA. This product has a two-pronged approach to health. First, it can be quite effective in reducing the debilitative effects of many of the diseases that are affecting the world today, such as COPD, diabetes, and cardiovascular illnesses. Secondly, Circularity’s D’OXYVA can be used in a preventative capacity to improve microcirculation. The concept of microcirculation has far-reaching implications in neurology, oncology, endocrinology, cardiovascular health, respiratory health, dermatology, diabetic wound healing or diabetic wound care and other major fields.

What “Behind The Scenes with Host Laurence Fishburne” Will Bring to the Table

Behind The Scenes has been an innovator in bringing information to the forefront in the public television space. The award-winning series features segments on the newest technologies, as well as fresh takes on existing entities, phenomenon, and natural occurrences. The show’s website boasts that the television series “highlights the evolution of education, medicine, science, technology and industry through inspiring stories.”

Aside from the Emmy-winning and Academy Award nominated actor Lawrence Fishburne as host, the program has an award-winning creative development team. Viewers walk away with a rich knowledge of the subject. Viewers may have known about this subject their whole lives, or it may be about something completely new. Viewers learn an evolving aspect of the topic which keeps the perspective fresh.

The dawning of a new age has appeared with this collaboration. Individuals who want to know more about what the health science field is bringing into our hospitals and doctors’ offices will not be disappointed. In today’s world, it is imperative that we are advocates for our own health.

Coming Soon: Miami ReLife’s Dr. Steven Gelbard

The first series is with Dr. Steven Gelbard, a nationally-famed authority with his ReLife Miami Institute on stem cells. Dr. Gelbard presents D’OXYVA’s Nobel Prize-winning science as a regenerative medicine. Dr. Gelbard is involving his direct contacts with top NFL players and other top sports celebrities in the monthly series, along with 25—40 top neurosurgeons and other experts working under ReLife.

Imagine having the ability to receive D’OXYVA and other innovative treatments and non-invasive procedures for chronic wound care amid the luxury of a five-star hotel. Behind The Scenes guest, Dr. Gelbard, a Tufts School of Medicine educated neurosurgeon, makes it happen right now. Medicine has left the hospital building and has become the proactive choice of the health conscious. We can all look forward to learning more about how to live a healthier and more informed lifestyle from this awe-inspiring episode.

According to Norbert Kiss, President and CEO of Circularity Healthcare, this collaboration is door busting. Mr. Kiss tells us, ”[We] can offer unprecedented access to this amazing Emmy-winning show called Behind the Scenes with very amazing terms due to our strategic involvement. We welcome any expert.”

Laurence Fishburne, host of Behind The Scenes,” beckons, “Join me as we all discover the endless ways to enjoy the skills and imagination.”

Don’t miss the evolution. It’s being televised. Circularity and Behind The Scenes—Stay tuned for a mind-fortifying experience!

Circularity Values:

We, at Circularity believe in a long-sought-after goal in health care; people should have access to one health application that solves most of their short and long term health issues without compromising other aspects of their health while doing this quickly, affordably, and without pain.
Circularity develops, manufactures and markets advanced technologies that significantly improve quality of life by improving some of the most essential physiological functions in the body.

About Behind The Scenes With Laurence Fishburne

Behind The Scenes is an award-winning program that highlights new stories and innovative concepts through groundbreaking short-form and long-form documentary presentation. The program, which is anchored by a veteran production team with decades of industry experience, is able to effectively communicate the most critical stories to a wide and diverse audience.

Behind The Scenes with Laurence Fishburne, has established an impressive and heralded career, amassing over one-hundred credits across the varied platforms of stage, television and film. He’s well known for major for roles in such films as; John Wick 2, Fantastic 4 Rise of the Silver Surfer, Mission Impossible III, Mystic River, Boyz n the Hood, What’s Love Got to Do With It, and Apocalypse Now. On the small screen, the award-winning and versatile actor played compelling roles in shows such as CSI: Crime Scene Investigation, CSI: Miami, CSI: New York and Hannibal. The Behind The Scenes Actor currently stars as Pops on the hit TV comedy Black-ish.

About Circularity Healthcare, LLC

Circularity Healthcare, LLC, located in Los Angeles, CA is a private biotech and MedTech products and services company that designs, makes, markets, sells, distributes and licenses its own patented and patent pending technologies, such as its flagship non-invasive deoxyhemoglobin vasodilator product line, D’OXYVA®. One of the main mechanisms underlying D’OXYVA’s science received the Nobel Prize for Medicine in 2019. Circularity enters into exclusive agreements with manufacturers to launch products and with large and small clinics and hospitals in order to help them enhance their profits and credit profiles with a wide variety of advanced products and services. In addition, Circularity Healthcare assists in the financing of equipment, working capital and also patient financing at industry-leading terms and speed.

Posted on Leave a comment

World-Famous Institute in Miami Has Reopened as ReLife Miami Institute Under the New Leadership of Famed Neurosurgeon Dr. Gelbard, Funding Led by Circularity Healthcare

The World-famous Institute in Miami, which specialized in cosmetic and plastic surgery as well as anti-aging and wellness treatments and catered to such famous celebrities as Kim Kardashian, has reopened as ReLife Miami Institute under the new leadership of famed neurosurgeon Dr. Steven Gelbard. ReLife Miami Institute is a private Florida Domestic Profit Corporation located at 1441 Brickell Avenue, Sky Lobby Suite, within the 5-star Four Seasons Hotel in Miami, Florida.

Read article in PRWeb

LOS ANGELES, October 24, 2019

ReLife Miami Institute™, which offers the latest in stem cell therapy and regenerative medicine through its ReLife Stem Cell Institute℠ as well as neurosurgical, orthopedic and pain management services, is now under the leadership of Steven Gelbard, MD a physician licensed in the state of Florida and board certified by the American Board of Hospital Physicians.

Dr. Gelbard is a leading neurosurgeon who has been practicing medicine in South Florida for over 20 years. He specializes in treating disorders of the brain, including bleeding in the brain, head and spinal trauma, neurological tumors, spinal disorders, and infections of the brain.

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.
“We conduct a 360-degree patient-centric evaluation and create a treatment plan with a dream team comprised of medical, nutritional, and wellness experts.” -Dr. Steven Gelbard ReLife Miami Institute, CEO

“I perform a number of procedures, including microsurgery, laser surgery, lumbar laminectomy, cervical laminectomy, evaluation and treatment of injuries to the brain and spine surgery for trauma to the brain and spine, reconstructive spinal surgery … as well as many other surgical procedures. We conduct a 360-degree patient-centric evaluation and create a treatment plan with a dream team comprised of medical, nutritional, and wellness experts.” —said Dr. Gelbard.

He received his medical degree from Tufts University School of Medicine in Boston and completed a surgical internship at New York University. Dr. Gelbard then graduated from the University of Vermont Neurosurgical Residency Program. Subsequently, he received additional training in neurosurgery and neurology at Brown University and Harvard University.

Dr. Gelbard has been granted several US patents for surgical instruments and has authored many publications in medical journals, including the Journal of Neurosurgery. Since 1991, Dr. Gelbard has operated a very successful private practice in a neurosurgery surgical center.

Circularity Healthcare, LLC, provides unique and advanced products and services for both small and large medical clinics and hospitals, helping them to structure financial transactions and obtain financing at very competitive terms in collaboration with its financing partners.

“We believe people should have access to a single medical device that solves a majority of their short- and long-term health issues quickly and without pain. D’OXYVA does that and much more when combined with stem cells and many other modalities. I am honored Dr. Gelbard’s ReLife selected our company, Circularity to manage and grow the new Miami Institute with industry-leading solutions that significantly improve chances of funding at terms that are difficult to beat by other market players.” —commented Norbert Kiss, President and CEO of Circularity.

“Circularity’s mission is giving people opportunities to interact with our brand, which definitely impacts customer acquisition rates positively. We care and that shows. As a registered nurse myself, my team’s first goal is to help patients.” —Jennifer Boadilla-Pelaez, Circularity’s Senior Sales and Marketing Manager and Creative Director supporting Relife’s marketing and public relations campaigns.

About ReLife Miami Institute

ReLife Miami Institute, LLC™ offers the latest in stem cell therapy and regenerative medicine through its ReLife Stem Cell Institute℠. It continues the long and successful history of the world-famous institute in Miami, offering plastic and reconstructive surgery, cosmetic products, IV therapy, dental surgery, sexual wellness, hair restoration, hormone replacement, anti-aging treatments and wellness counseling. ReLife Miami Institute is located inside the 5-star Four Seasons Miami hotel in Miami, Florida.

About Circularity Healthcare, LLC

Circularity Healthcare, LLC, located in Los Angeles, CA is a private biotech and MedTech products and services company that designs, makes, markets, sells, distributes and licenses its own patented and patent pending technologies, such as its flagship non-invasive deoxyhemoglobin vasodilator product line, D’OXYVA®. One of the main mechanisms underlying D’OXYVA’s science received the Nobel Prize for Medicine in 2019. Circularity enters into exclusive agreements with manufacturers to launch products and with large and small clinics and hospitals in order to help them enhance their profits and credit profiles with a wide variety of advanced products and services. In addition, Circularity Healthcare assists in the financing of equipment, working capital and also patient financing at industry-leading terms and speed.

Posted on Leave a comment

Science underlying D’OXYVA receives the Nobel Prize in Physiology for Medicine in 2019

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

The Nobel Assembly at Karolinska Institutet has today decided to award the 2019 Nobel Prize in Physiology for Medicine jointly to William G. Kaelin Jr., Sir Peter J. Ratcliffe and Gregg L. Semenza for their discoveries of how cells sense and adapt to oxygen availability.

SUMMARY


Animals need oxygen for the conversion of food into useful energy. The fundamental importance of oxygen has been understood for centuries, but how cells adapt to changes in levels of oxygen has long been unknown.

William G. Kaelin Jr., Sir Peter J. Ratcliffe and Gregg L. Semenza discovered how cells can sense and adapt to changing oxygen availability. They identified molecular machinery that regulates the activity of genes in response to varying levels of oxygen.

The seminal discoveries by this year’s Nobel Laureates revealed the mechanism for one of life’s most essential adaptive processes. They established the basis for our understanding of how oxygen levels affect cellular metabolism and physiological function. Their discoveries have also paved the way for promising new strategies to fight anemia, cancer and many other diseases.

Oxygen at center stage


Oxygen, with the formula O2, makes up about one fifth of Earth’s atmosphere. Oxygen is essential for animal life: it is used by the mitochondria present in virtually all animal cells in order to convert food into useful energy. Otto Warburg, the recipient of the 1931 Nobel Prize in Physiology or Medicine, revealed that this conversion is an enzymatic process.

During evolution, mechanisms developed to ensure a sufficient supply of oxygen to tissues and cells. The carotid body, adjacent to large blood vessels on both sides of the neck, contains specialized cells that sense the blood’s oxygen levels. The 1938 Nobel Prize in Physiology or Medicine to Corneille Heymans awarded discoveries showing how blood oxygen sensing via the carotid body controls our respiratory rate by communicating directly with the brain.

 

HIF enters the scene


In addition to the carotid body-controlled rapid adaptation to low oxygen levels (hypoxia), there are other fundamental physiological adaptations. A key physiological response to hypoxia is the rise in levels of the hormone erythropoietin (EPO), which leads to increased production of red blood cells (erythropoiesis). The importance of hormonal control of erythropoiesis was already known at the beginning of the 20th century, but how this process was itself controlled by O2 remained a mystery.

Gregg Semenza studied the EPO gene and how it is regulated by varying oxygen levels. By using gene-modified mice, specific DNA segments located next to the EPO gene were shown to mediate the response to hypoxia. Sir Peter Ratcliffe also studied O2-dependent regulation of the EPO gene, and both research groups found that the oxygen sensing mechanism was present in virtually all tissues, not only in the kidney cells where EPO is normally produced. These were important findings showing that the mechanism was general and functional in many different cell types.

Semenza wished to identify the cellular components mediating this response. In cultured liver cells he discovered a protein complex that binds to the identified DNA segment in an oxygen-dependent manner. He called this complex the hypoxia-inducible factor (HIF) . Extensive efforts to purify the HIF complex began, and in 1995, Semenza was able to publish some of his key findings, including identification of the genes encoding HIF. HIF was found to consist of two different DNA-binding proteins, so called transcription factors, now named HIF-1α and ARNT. Now the researchers could begin solving the puzzle, allowing them to understand which additional components were involved and how the machinery works.

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.
Figure 1. When oxygen levels are low (hypoxia), HIF-1α is protected from degradation and accumulates in the nucleus, where it associates with ARNT and binds to specific DNA sequences (HRE) in hypoxia-regulated genes (1). At normal oxygen levels, HIF-1α is rapidly degraded by the proteasome (2). Oxygen regulates the degradation process by the addition of hydroxyl groups (OH) to HIF-1α (3). The VHL protein can then recognize and form a complex with HIF-1α leading to its degradation in an oxygen-dependent manner (4).

​VHL: an unexpected partner


When oxygen levels are high, cells contain very little HIF-1α. However, when oxygen levels are low, the amount of HIF-1α increases so that it can bind to and thus regulate the EPO gene as well as other genes with HIF-binding DNA segments (Figure 1). Several research groups showed that HIF-1α, which is normally rapidly degraded, is protected from degradation in hypoxia. At normal oxygen levels, a cellular machine called the proteasome, recognized by the 2004 Nobel Prize in Chemistry to Aaron Ciechanover, Avram Hershko and Irwin Rose, degrades HIF-1α. Under such conditions a small peptide, ubiquitin, is added to the HIF-1α protein. Ubiquitin functions as a tag for proteins destined for degradation in the proteasome. How ubiquitin binds to HIF-1α in an oxygen-dependent manner remained a central question.

The answer came from an unexpected direction. At about the same time as Semenza and Ratcliffe were exploring the regulation of the EPO gene, cancer researcher William Kaelin, Jr. was researching an inherited syndrome, von Hippel-Lindau’s disease (VHL disease). This genetic disease leads to dramatically increased risk of certain cancers in families with inherited VHL mutations. Kaelin showed that the VHL gene encodes a protein that prevents the onset of cancer. Kaelin also showed that cancer cells lacking a functional VHL gene express abnormally high levels of hypoxia-regulated genes; but that when the VHL gene was reintroduced into cancer cells, normal levels were restored. This was an important clue showing that VHL was somehow involved in controlling responses to hypoxia. Additional clues came from several research groups showing that VHL is part of a complex that labels proteins with ubiquitin, marking them for degradation in the proteasome. Ratcliffe and his research group then made a key discovery: demonstrating that VHL can physically interact with HIF-1α and is required for its degradation at normal oxygen levels. This conclusively linked VHL to HIF-1α.

Oxygen sHIFts the balance


Many pieces had fallen into place, but what was still lacking was an understanding of how O2 levels regulate the interaction between VHL and HIF-1α. The search focused on a specific portion of the HIF-1α protein known to be important for VHL-dependent degradation, and both Kaelin and Ratcliffe suspected that the key to O2-sensing resided somewhere in this protein domain. In 2001, in two simultaneously published articles they showed that under normal oxygen levels, hydroxyl groups are added at two specific positions in HIF-1α (Figure 1). This protein modification, called prolyl hydroxylation, allows VHL to recognize and bind to HIF-1α and thus explained how normal oxygen levels control rapid HIF-1α degradation with the help of oxygen-sensitive enzymes (so-called prolyl hydroxylases). Further research by Ratcliffe and others identified the responsible prolyl hydroxylases. It was also shown that the gene activating function of HIF-1α was regulated by oxygen-dependent hydroxylation. The Nobel Laureates had now elucidated the oxygen sensing mechanism and had shown how it works.

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.
Figure 2. The awarded mechanism for oxygen sensing has fundamental importance in physiology, for example for our metabolism, immune response and ability to adapt to exercise. Many pathological processes are also affected. Intensive efforts are ongoing to develop new drugs that can either inhibit or activate the oxygen-regulated machinery for treatment of anemia, cancer and other diseases.

Oxygen shapes physiology and pathology

Thanks to the groundbreaking work of these Nobel Laureates, we know much more about how different oxygen levels regulate fundamental physiological processes. Oxygen sensing allows cells to adapt their metabolism to low oxygen levels: for example, in our muscles during intense exercise. Other examples of adaptive processes controlled by oxygen sensing include the generation of new blood vessels and the production of red blood cells. Our immune system and many other physiological functions are also fine-tuned by the O2-sensing machinery. Oxygen sensing has even been shown to be essential during fetal development for controlling normal blood vessel formation and placenta development.

Oxygen sensing is central to a large number of diseases (Figure 2). For example, patients with chronic renal failure often suffer from severe anemia due to decreased EPO expression. EPO is produced by cells in the kidney and is essential for controlling the formation of red blood cells, as explained above. Moreover, the oxygen-regulated machinery has an important role in cancer. In tumors, the oxygen-regulated machinery is utilized to stimulate blood vessel formation and reshape metabolism for effective proliferation of cancer cells. Intense ongoing efforts in academic laboratories and pharmaceutical companies are now focused on developing drugs that can interfere with different disease states by either activating, or blocking, the oxygen-sensing machinery.

HOW D’OXYVA CAN HELP?

D’OXYVA is the only fully noninvasive, completely painless transdermal (over-the-skin) oxygen-balanced microcirculatory solution that has been clinically tested to significantly improve microcirculation.

The improvement of oxygen-balanced microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Posted on Leave a comment

Circularity Healthcare Negotiating $100 million Institutional Funding, Expands Successful D’OXYVA Phase 3 Diabetic Foot Ulcer Treatment Clinical Trials, Expects Fast-Track FDA Approval

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

Read Article in PRWeb

[Los Angeles, CA, July 16, 2019] Circularity Healthcare LLC, developer and manufacturer of transdermal drug delivery and wound healing products, has announced that the company has entered into negotiations with institutional investors to inject up to $100 million in growth capital into the company. The capital is to be used to drive Circularity’s launch of product sales in collaboration with several global multinational partners, with a target of several hundred million dollars. The company’s overarching fundraising goal is to access public equity markets through a multibillion-dollar U.S. IPO in the near future.

Privately-held, Los Angeles-based Circularity Healthcare is capitalizing on its completed successful and expanded Phase 3 clinical studies led by prominent researchers, such as Prof. David Armstrong, Prof. Ito Puruhito and Dr. Felix Sigal, and leading institutions, such as MIT, Airlangga, Harvard, Yale, University of Texas at Arlington, and many others. The clinical studies are expected to lead to the company’s highly anticipated Food and Drug Administration FDA approval as a non-significant risk (NSR) combination drug-device for the rapid and highly effective treatment of diabetic foot ulcers.

These exciting developments come on the heels of the rapidly growing market demand for Circularity’s existing product line with a proven technology, manufacturing and fulfillment base. Circularity has recently begun production of its unique, branded, pharmaceutical-grade platform drug molecules.

Already well positioned as an emerging global biotech and MedTech product manufacturer, Circularity is now shifting more focus from its non-regulated wellness and cosmetic products to its premium FDA-approved patented and patent-pending drug solutions. These solutions are delivered with the company’s patented and patent pending, non-invasive and painless, rapid transdermal drug delivery systems. The expanded focus is due to Circularity’s exceptionally positive Phase 3 multicenter, multicountry, and multiyear human clinical trials on diabetic foot ulcers, as well as its overall regulatory development path.

Recently, the company launched sales of MicroScan, a clinical diagnostics tool with an installed base at intensive care units (ICU) in 35 countries worldwide. MicroScan enables Circularity to generate much higher average revenue per customer, while providing highly affordable insights, both for patients and health professionals, into the inner workings and mechanisms of actions underpinning the exceptional clinical outcomes of Circularity’s flagship D’OXYVA product line. Until recently, D’OXYVA was available only under test-marketing programs. Together with the diagnostic tools, health experts implementing D’OXYVA can accurately predict wound healing and other major clinical outcomes, such as achieving healthy blood sugar or blood pressure.

Once D’OXYVA has helped the patient achieve healthy levels in such key areas, physicians typically recommend a less frequent dosing schedule in order to remain symptom-free long-term.

During the past seven years, Circularity has assembled a world-class clinical research, regulatory and legal team comprised of several dozen experts mainly from the U.S. and from several influential European and Asian countries for its comprehensive global market development.